Literature DB >> 7576109

Analysis of oncogenes, tumor suppressor genes, autocrine growth-factor production, and differentiation state of human osteosarcoma cell lines.

R J Isfort1, D B Cody, G Lovell, C J Doersen.   

Abstract

Human osteosarcoma and fibrosarcoma cell lines were investigated for alterations in oncogenes, tumor suppressor genes, and growth factors, all of which have been implicated in tumor formation. Characterization of oncogenes that are involved in osteosarcoma formation, including the c-fos and c-myc oncogenes, indicated that all six osteosarcoma cell lines examined had 5- to 20-fold amplification of the c-myc oncogene, whereas neither of two fibrosarcoma cell lines c-myc amplification. Interestingly, only three of six osteosarcoma cell lines displayed altered c-myc immediate-early gene function. c-fos was found to be normal, both at the gene and functional levels, in all six osteosarcoma and both fibrosarcoma cell lines tested. Characterization of two tumor suppressor genes, p53 and RB1, that have been implicated in osteosarcoma formation indicated that p53 was altered in five of six osteosarcoma cell lines, whereas RB1 was altered in only two or six of these cell lines. Neither RB1 nor p53 was found to be altered in the fibrosarcoma cell lines tested. An additional transformation marker, autocrine growth-factor production, was observed in all six osteosarcoma cell lines and both fibrosarcoma cell lines examined. Finally, the differentiation state of the osteosarcoma cell lines was investigated via the bone differentiation markers alkaline phosphates and osteocalcin. Alkaline phosphatase activity was observed in four of six osteosarcoma cell lines but not in the two fibrosarcoma cell lines examined. The alkaline phosphatase activity was a result of the expression of the bone/liver/kidney alkaline phosphatase isoform. High-level osteocalcin expression was observed in one of the osteosarcoma cell lines but not in the two fibrosarcoma cell lines examined, although all cell lines demonstrated low-level osteocalcin expression. Together, these data demonstrate that relatively undifferentiated osteosarcomas commonly display c-myc amplification, p53 and RB1 mutation, and autocrine growth-factor production, all of which may play a role in osteosarcomagenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576109     DOI: 10.1002/mc.2940140306

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis.

Authors:  D P Satijn; D J Olson; J van der Vlag; K M Hamer; C Lambrechts; H Masselink; M J Gunster; R G Sewalt; R van Driel; A P Otte
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

2.  Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Haoqiang Zhang; Peng Gao; Bo Fan; Chen Huang; Jun Fu; Guojing Chen; Lei Shi; Haodong Zhu; Xiangdong Li; Jing Li; Hongbin Fan; Zhigang Wu; Zheng Guo; Yongcheng Hu; Sujia Wu; Xiuchun Yu; Cheng Xu; Zhen Wang
Journal:  Tumour Biol       Date:  2014-11-28

3.  P53 Overexpression as an Indicator of Overall Survival and Response to Treatment in Osteosarcomas.

Authors:  Zsuzsa Pápai; Christina N Féja; Eid N Hanna; Mariann Sztán; Edit Oláh; Miklós Szendrôi
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

4.  High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.

Authors:  Zhihong Wang; Jun-Ying Zhou; Deepa Kanakapalli; Steven Buck; Gen Sheng Wu; Yaddanapudi Ravindranath
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

5.  Comparison of the reaction of bone-derived cells to enhanced MgCl2-salt concentrations.

Authors:  Anna Burmester; Bérengère Luthringer; Regine Willumeit; Frank Feyerabend
Journal:  Biomatter       Date:  2014
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.